Share This Page
Drugs in ATC Class D02BB
✉ Email this page to a colleague
Drugs in ATC Class: D02BB - Protectives against UV-radiation for systemic use
| Tradename | Generic Name |
|---|---|
| SCENESSE | afamelanotide |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class D02BB protectives against UV radiation for systemic use
Executive summary:
ATC D02BB “Protectives against UV-radiation for systemic use” covers oral and other systemic UV-protective actives used to reduce sunburn and UV-driven photoaging risk. The patent landscape is dominated by small-molecule nutraceuticals and dermatology-adjacent formulations rather than large, single-branded biologics franchises. IP protection typically concentrates in (i) specific active combinations (e.g., carotenoids, polyphenols, omega-3s, sunscreen adjunct complexes), (ii) dosage forms and dose regimens optimized for measurable photoprotection endpoints (minimal erythema dose, UV-induced biomarker panels), and (iii) manufacturing/standardization methods. Patent expiration and exclusivity timing tends to be staggered across jurisdictions, creating a fragmented generics or “equivalents” entry risk profile rather than a single clear loss-of-exclusivity event.
What this means commercially: market entry pressure is usually driven by substantiation requirements and brand-level clinical evidence, not by a clean “Orange Book-style” generic pathway. The most enforceable rights in this class often sit in formulation and method-of-use patents tied to defined dosing regimens and specific compositions.
What active ingredients and products sit in ATC D02BB protectives against UV radiation for systemic use?
Featured snippet answer: ATC D02BB systemics are oral UV-protective products built around carotenoids (notably beta-carotene and/or mixed carotenoids like lycopene), polyphenols/antioxidants, and other photo-protective dietary actives, with claims anchored to reduced erythema and improved tolerance to UV exposure.
Common systemic UV-protection categories
- Carotenoids: beta-carotene, lycopene, lutein/zeaxanthin mixes; used for antioxidant and oxidative-stress modulation tied to photoprotection endpoints.
- Polyphenols and plant extracts: grape seed polyphenols, green tea catechins, cocoa flavanols and related fractions, depending on product.
- Lipid and omega-3 adjuncts: used for anti-inflammatory or skin-barrier-related pathways; often paired with carotenoids or polyphenols in combination systems.
- Combinations and multi-ingredient “complexes”: the dominant IP target in this class because combinations let sponsors claim improved or different UV-protection performance than single actives.
How products typically differentiate
- Dose and regimen: daily dosing duration prior to UV exposure and ongoing administration.
- Standardization: defined extract specs or standardized carotenoid forms.
- Clinical endpoint alignment: minimal erythema dose (MED) shifts, sunburn incidence reduction, UV-induced biomarker changes, photoaging metrics.
- Device-like claims without being devices: marketing often resembles functional dermatology, but the regulatory posture varies by country (food supplement vs. drug vs. medical nutrition depending on jurisdiction).
Which companies lead ATC Class D02BB systemic UV protectives and what commercial momentum matters?
Featured snippet answer: The lead players tend to be consumer-health dermatology brands and ingredient-based companies that license standardized actives and clinical packages into finished-dose products.
Commercial dynamics that shape demand
- Seasonality: northern-hemisphere demand peaks in late spring through summer; IP enforcement and launch timing often track pre-season stocking cycles.
- Regulatory posture: in markets where these products are marketed as supplements, claims are constrained and patent value tilts toward formulation and substantiation.
- Evidence threshold: even where not “drug-subject,” clinical validation is used as proof to justify premium pricing and distributor adoption.
- Channel strategy: pharmacies and dermatology clinics push higher-ticket products; e-commerce drives rapid SKU proliferation, raising the risk of “design-around” formulation entries.
Typical competitive pattern
- A sponsor builds an evidence package for a defined composition and dose schedule.
- Competitors enter with either (i) close combinations at different dosages or (ii) alternate standardized extracts.
- Brand leaders defend via formulation patents and method-of-use claims tied to the clinical endpoints and timing.
What patents protect systemic UV protectives (D02BB) most effectively?
Featured snippet answer: The strongest and most litigable IP in D02BB is usually composition-of-matter and formulation patents paired with method-of-use patents that define specific dosing regimens to achieve measurable photoprotection outcomes.
Patent clusters by claim type
- Composition of matter (direct or dependent)
- combinations of carotenoids, polyphenols, and anti-oxidant lipids
- specific ratio ranges and defined standardized contents (mg/day equivalents)
- Formulation and dosage form
- oil-based carriers for carotenoid bioavailability
- encapsulation and release profiles (softgels, emulsions, microencapsulation)
- stability and standardization methods to preserve actives through shelf life
- Method-of-use
- administration schedule before and during UV exposure
- use to increase MED or reduce erythema incidence
- use to mitigate UV-induced biomarker shifts (where claim language supports it)
- Manufacturing methods
- extract fractionation and standardization procedures
- blending/mixing processes preserving component activity and bioavailability
Where design-arounds occur
- Replace one component with a non-infringing analog (different carotenoid profile or alternative polyphenol source).
- Change dosage ratio so the composition claims do not read on the competitor’s product.
- Adjust regimen timing so method-of-use claims tied to “X weeks before UV” do not apply.
When do D02BB systemic UV protection patents typically expire and how does timing shape generic or “equivalent” entry?
Featured snippet answer: There is no single class-wide exclusivity end date. Instead, entry risk rises when key composition and method-of-use families expire in each target jurisdiction, often leaving only formulation improvements or newer claims as barriers.
How expiry risk is structured
- Basic patent term: generally 20 years from earliest priority filing, subject to adjustments.
- Patent family stagger: multiple priority dates produce a staggered expiration ladder across compositions and methods.
- Jurisdictional variance: different national phase timelines and term adjustments create uneven “last-to-expire” markets.
Practical launch sequencing
- Sponsors often “pre-position” improved line extensions before expiry to keep branded market share.
- Competitors typically time entry around:
- expiration of the broad composition claims,
- narrowing or invalidation risk of method-of-use claims,
- availability of clinically comparable evidence packages for substituted combinations.
How do Paragraph IV challenges or FDA-style exclusivity concepts apply to systemic UV protectives?
Featured snippet answer: Paragraph IV is a mechanism for ANDA drug exclusivity under Hatch-Waxman, tied to FDA-regulated listed drugs. Many D02BB systemic UV protectives operate in regulatory spaces closer to supplements or non-ANDA product categories, so the “Orange Book + Paragraph IV” model is often not the governing entry framework. When products are regulated as drugs, exclusivity and listed-drug pathways can matter, but the class is commonly fragmented.
Regulatory pathways that affect IP leverage
- If marketed as dietary supplements / foods (many markets): IP competition shifts to trademark, substantiation, and patents on composition/formulation rather than generic-drug approval mechanics.
- If marketed as OTC or prescription drugs (some jurisdictions): the legal and exclusivity framework resembles drug markets with potential Orange Book-like considerations, but the practical applicability varies by country.
What is the Orange Book status of D02BB systemic UV protectives?
Featured snippet answer: Orange Book status is product-specific and depends on whether the product is a “listed drug” approved under the relevant U.S. drug scheme. The class definition alone does not map to a single Orange Book listing.
How to think about status for market access
- If a U.S. product is not a listed drug, Orange Book-driven litigation pathways do not anchor entry barriers.
- If a product is a listed drug, then:
- expiration dates,
- patent listings (drug substance, drug product, method-of-use),
- and litigation records
determine the real exclusivity end game.
What patent litigation affects systemic UV protectives, and what claims are usually asserted?
Featured snippet answer: When disputes occur, sponsors typically assert formulation and method-of-use patents tied to defined compositions and clinically measurable photoprotection outcomes, aiming for injunction leverage rather than damages-only strategies.
Typical asserted claim themes
- Patent covers a specific composition range (carotenoid/polyphenol/antioxidant complex).
- Patent covers a dosing regimen and UV exposure timing.
- Patent covers bioavailability-enhancing formulation approaches (carriers/encapsulation).
Defenses and counter-strategies
- Non-infringement via composition changes or different dosing schedule.
- Invalidity defenses based on prior art showing similar combinations and methods.
How strong is the patent estate for D02BB systemic UV protectives versus sunscreens (topical UV filters)?
Featured snippet answer: Patent estates in D02BB systemic UV protectives tend to be narrower and more formulation- and method-dependent than the broader topical sunscreen landscape, where active UV filter chemistry and broad formulation IP can be heavier. In systemic products, competitors can often design around by altering ratios, standardized extract sources, and dosing schedules.
Comparison with topical UV protection markets
- Topical sunscreens: often anchored to UV-filter actives and regulatory approval dossiers for those actives.
- Systemic protectives: often anchored to combinations, clinical evidence, and bioavailability/formulation improvements tied to antioxidants and carotenoids.
Which formulation patents matter most for systemic UV protection (dosage forms, carriers, and bioavailability)?
Featured snippet answer: For carotenoid- and polyphenol-based systemic UV protection, formulation patents that control bioavailability and stability tend to be the most defensible barriers to fast equivalence.
Key formulation mechanics that are patent-sensitive
- Encapsulation: softgel matrices, microencapsulation, or other controlled-release systems.
- Carrier selection: lipid carriers for carotenoid absorption.
- Stability: antioxidant systems preventing oxidative degradation of actives during shelf life.
- Standardization methods: defined phenolic profiles and carotenoid assay methods to guarantee consistent clinical performance.
Why this matters for infringement
Design-around is easier when the barrier is a single active ingredient. It is harder when the competitor would have to replicate the exact formulation mechanics and regimen tied to clinical results.
How do method-of-use patents shape biosimilar-like risks and “equivalent” competition for systemic UV protectives?
Featured snippet answer: “Biosimilar” is not the right legal construct for these small-molecule dietary actives. Risk comes instead from method-of-use claims and clinical substantiation requirements that tie product use to measurable endpoints.
Risk channels
- If method-of-use claims are broad: competitors can face injunction risk even with modified composition if their regimen and intended use map to claimed steps.
- If method-of-use claims are narrow: risk shifts to composition equivalence and clinical performance evidence.
What generic entry risks exist for D02BB systemic UV protectives?
Featured snippet answer: The highest generic-like entry risk typically appears after expiry of broad composition/formulation families. Even then, enforcement may migrate to remaining patents covering specific extract standards, carrier systems, or dosing regimens.
Entry risk ladder
- Phase 1: carve-out entrants
- use different component ratios and substituted sources
- Phase 2: regimen-matched entrants
- mirror dosing schedule to meet performance claims, creating method-of-use exposure
- Phase 3: full replacement entrants
- move close to the original composition once core composition claims are expired or weakened
Which jurisdictions provide the clearest enforceability for D02BB systemic UV patents?
Featured snippet answer: Jurisdiction strength aligns with where patent families were filed and prosecuted. Enforcement is usually most practical in major markets where finished-dose product distribution is concentrated.
Typical filing geography
- Europe (EP validation and national enforcement)
- U.S.
- Japan
- selected additional markets depending on target sales
How geography changes outcomes
- A product can launch in a low-enforcement jurisdiction while facing injunction risk in high-enforcement markets.
- Trade and parallel import dynamics can also become a pressure point for enforcement strategy.
Key takeaways
- ATC D02BB systemic UV protectives are a formulation- and evidence-driven category where patents typically cluster around composition combinations, bioavailability/stability formulation, and method-of-use dosing regimens tied to photoprotection endpoints.
- Patent expiration is staggered by family and jurisdiction; market entry risk rises as broad composition claims fall, but enforcement can continue via narrower formulation or regimen patents.
- Paragraph IV and Orange Book frameworks are often not the central entry lever unless specific products are FDA-listed drugs; many market entries behave more like supplement “equivalents” where IP leverage rests on formulation and clinical substantiation.
- Competitive pressure is most acute when sponsors have not refreshed line extensions with new patentable formulation or method-of-use improvements ahead of expiration.
FAQs
1) What types of patents are most commonly infringed for systemic UV protection supplements and drugs?
Composition-of-matter, formulation/bioavailability patents (carriers and encapsulation), and method-of-use patents specifying administration timing and UV-protection endpoints.
2) Do systemic UV protectives face generic competition like traditional pharmaceuticals?
When regulated as non-drug products, competition is typically “equivalent” rather than ANDA-based. When regulated as drugs, exclusivity and listed-drug frameworks can apply but are product-specific.
3) How do companies design around systemic UV protection patents?
They alter component sources or ratios, change standardized extract profiles, and adjust dosing schedules to avoid method-of-use claim coverage.
4) What clinical endpoints are commonly tied to method-of-use claims?
Minimal erythema dose changes, reduced sunburn incidence, and UV-induced biomarker improvements that support claimed photoprotection.
5) Where should diligence focus when assessing freedom to operate for D02BB systemic UV products?
Freedom-to-operate reviews should prioritize active combination patents, dosage regimen method claims, and formulation patents controlling bioavailability and stability in the finished dosage form.
References (APA)
- World Health Organization Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC/DDD Index. https://www.whocc.no/atc_ddd_index/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book (where applicable). https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Patent and Trademark Office. (n.d.). Patent term and adjustment basics (general information). https://www.uspto.gov/
More… ↓
